Author Archives: admin


Chinese Researchers Created the First PigMonkey Chimera – Science Times

(Photo : Pixabay)

Chinese researchers developed two piglets that were a hybrid of a pig and a monkey.

Monkey stem cells were injected into fertilized pig embryos to generate the pigmonkey chimera. These were subsequently implanted intosurrogate sows.Chimeras were a result of these piglets, which means that they contained DNA from a pig and a monkey.

"This is the first report of full-term pig-monkey chimeras," co-author Tang Hai, a researcher at the State Key Laboratory of Stem Cell and Reproductive Biology in Beijing, told New Scientist.

The main goal of Hai and his co-researchers were for the growth of human organs in animals for transplant procedures. The team has received ethical qualms related to the development ofhumananimal chimeras.

Mechanism on the Growth of the PigMonkey Chimera

The cells of cynomolgus monkeys (Macaca fascicularis) were grown in lab dishes. TheDNA cellswere provided steps to build a fluorescent protein that aimed to change the DNA. A bright green glow was a result of this protein. Embryonic stem cells resulted from these luminescent cells that were injected into prepared pig embryos. Monkey cells were tracked by the researchers through these luminescent spots.

A total of 4,000 embryos were recipients of the monkey cell injection and were subsequently implanted in surrogate pigs. Ten piglets were born out of these sows but only two grew both pig and monkey cells. The team used the luminescent protein to scan for the monkey cells through different organs. The hybrid chimeras were comprised of 99% pig as there is one in 1,000 monkey cells in each organ.

The low ratio of monkey to pig cells still is greater compared with the 2017 humanpig chimera that was grown by scientists. The said chimera was only permitted to develop for a month since there is a possibility that the brain might grow human cells and provide the animal with a human-like consciousness.

Ethical Issues

The pressure from the scientific ethics committee did not stop the team from creating humanmonkey chimeras early this 2019. The results of the said experiment were not published, but the researchers only allowed the humanprimate chimera a few weeks to develop.

Despite the success achieved by Hai and his co-authors, stem cell biologist Paul Knoepler of the University of California, Davis was not impressed with the results as it is discouraging because of the low ration of monkey-to-pig cells.

"The exact reason for the piglets' death remains "unclear," Hai told New Scientist, but he said that he suspects the deaths are linked to the in vitro fertilization (IVF) procedure rather than the injection of monkeyDNA. Other scientists have also found that IVF doesn't consistently work in pigs, according to a 2019 report in the journalTheriogenology," as reported byLive Science.

Hai and his team aim to increase the ratio of monkey cells to pig cells in future chimeras. The researchers aim to be able to grow human organs in animals for organ transplant procedures and to help in the field of human health.

Go here to read the rest:
Chinese Researchers Created the First PigMonkey Chimera - Science Times

A Modern Treatment for the Age-Old Problem that is Hair Loss – Communal News

Hair loss is one of those things that can be incredibly detrimental to numerous parts of a persons life. This problem is not one that only affects people aesthetically; its often something that can be really detrimental to a persons confidence to the point it can lead to social isolation and difficulties in the workplace. While some people are quite happy to get out the clippers and call it a day, for a lot of people their hair is extremely important to them and a huge part of how they express and represent themselves to others, and when this is taken away from them it can be a significant shock.

Hair Transplants Work But Arent Always Ideal

If you are contemplating hair transplant procedures, you are likely somewhat aware of the process already, but there are a few things that people that receive hair transplants often have to say about them which you may not be aware of yet. While they do work, in some circumstances very well, they are time-intensive, uncomfortable and can lead to scarring. Depending on the amount of hair you are having transplanted you may be in the chair for a very long time, and depending on the amount of hair that survives the transplant you may end up requiring even more time.

Many people also find the popping sensation of this treatment quite uncomfortable, and when the treatment is quite time-intensive, this can become something far less than pleasant. There is also the issue of scarring, and if you are concerned, you may end up losing more hair over time or end up with significant balding this may leave you with not just a bald head, but now a scarred one as well. Modern approaches to hair transplants using direct follicle transplant are far better in this regard than the older method of using strips, but this is still something to be aware of when thinking about this treatment option for hair loss.

Hair Loss is Complicated

Hair loss is extremely complex, and its frequently understated how much so when the reality is there are so many potential causes for hair loss and types of hair loss the same treatments arent ideal for everyone. Often a secondary condition may be causing the hair loss that needs to be addressed. Its essential that you seek the assistance of someone experienced in treating hair loss rather than trying to mask it yourself with off the shelf products, wigs, or less than ideal products like spray-on hair.

An Interesting Treatment for a Difficult Condition

However, one treatment that is growing in popularity and is suitable for a lot of people is PRP hair loss treatment using platelet-rich plasma injections. What makes this treatment quite interesting is that it takes advantage of mechanisms present in your own body and amplifies them by concentrating specific elements of your blood. While this can sound quite dramatic, for patients receiving PRP hair loss treatment, its actually not; it merely requires a small blood sample that is then processed and prepared for reinjection. PRP injections when used to treat hair loss are then applied with a series of precision injections into the scalp. Over 30 growth factors have been identified in platelets, so when the platelets are concentrated from a blood sample and activated by calcium chloride, they have an often impressive effect on hair regeneration when applied to the scalp.

Hits: 52

Related

Read the original post:
A Modern Treatment for the Age-Old Problem that is Hair Loss - Communal News

Global Joint Pain Injections Market || What are the Key market Trends and Dynamics? – Sound On Sound Fest

GlobalJoint Pain Injections Marketis the title of a recently researched market, and is based on the current global scenario, and is in the process of completion at MarketResearch.biz. It contains information and data that have been verified and based on considerations, opinions, and inputs from experts in the industry. Exhaustive primary and secondary research efforts have also been invested largely to ensure the report will provide accurate insights into the target market. Sales, deployment, and revenue are based on historical revenue, estimated revenue, and projected revenue. Various geopolitical and political factors are considered to enable presentation of all findings.

Besides tactical data and information, the report includes key and ongoing trends, factors that are driving market growth, and factors that are potential restraints to growth of the market. [Download FREE Sample PDF Here Now] Y-O-Y growth, future forecast & opportunity analysis is also presented. Opportunities that can be leveraged for potential revenue generation in untapped regions and countries, as well as threats or challenges are also presented in the respective sections of the report. Company profiles of key players include detailed information, recent developments, strategies, and acquisitions and mergers etc. The global Joint Pain Injections systems report is segmented based on type, end-user, and region. Regions are further sub-segmented at country level, and revenues for each segment presented according to each region and country.

For Better Understanding Go With this Free Sample Report Enabled with Respective Tables and Figures:https://marketresearch.biz/report/joint-pain-injections-market/request-sample

Top Players present in global Joint Pain Injections market are:Allergan Plc., Pfizer Inc, Sanofi, Anika Therapeutics Inc, Ferring B.V., Bioventus LLC, Flexion Therapeutics Inc, Zimmer Biomet Holdings Inc, Seikagaku Corporation, Chugai Pharmaceutical Co Ltd

An extensive analysis report of the Joint Pain Injections Market options crucial growth opportunities within the market which will assist the market user to set up the business strategy for his or her future expansions in the worldwide industry in an exceedingly specific region. All the statistical data and different data area unit comprehensively crafted to helps the particular user to explore their business showing wisdom.

Be the Lucky Santa of Your Happy Business!

The segmentation details of the Joint Pain Injections industry are as follows:

Segmentation by Injection type:

Corticosteroid InjectionsHyaluronic Acid InjectionsOthers (include, Platelet-rich plasma (PRP), Placental tissue matrix (PTM), etc.)Segmentation by joint type:

Knee & AnkleHip JointShoulder & ElbowFacet Joints of the SpineOthers (include, Ball and socket, etc.)Segmentation by end-user:

Hospital PharmaciesRetail PharmaciesOnline Pharmacies

Joint Pain Injections market by geological regions: Europe, Africa, North America, Asia-Pacific, Middle East, United Kingdom, and Latin America.

Joint Pain Injections Market Report Structure at a Glance:

1) To gain insightful analyses of the market and have a comprehensive understanding of Joint Pain Injections and its commercial landscape.

2) Extensive analysis of the current trends and future estimations in the world Joint Pain Injections market is provided in the report

3) Joint Pain Injections report provides a competitive outline of the market with growth trends, driving factors, scope, opportunities, challenges

4) Joint Pain Injections Study comprises an in-depth analysis of the key segments to provide insights on the market dynamics

5) Porters Five Forces analysis highlights the potential of buyers and suppliers as well as provides insights on the competitive structure of the market to devise effective growth strategies and facilitate better decision-making

6) Value chain analysis provides key inputs on the role of stakeholders involved at various stages

7) The report will be very useful to get a stronger and effective business outlook.

If you have any Customization need to be added, we are happy to servehttps://marketresearch.biz/report/joint-pain-injections-market/#request-for-customization

Contact Us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

Go here to see the original:
Global Joint Pain Injections Market || What are the Key market Trends and Dynamics? - Sound On Sound Fest

Exclusive Research On Joint Pain Injections Market SWOT Analysis including Key Players – Sound On Sound Fest

MarketResearch.Biz added the most up-to-date research on Joint Pain Injections Market, Forecast to 2029 to its comprehensive list of research reports. An insight on the important factors and trends influencing the market competition and opportunities in Investment.

Joint Pain Injections Market research report gives a comprehensive data and analysis about the worldwide Joint Pain Injections market. The report further gives the data that one could rely on; which comes with an in-depth analysis of Joint Pain Injections market. Different factors like in-depth description of Joint Pain Injections market, growth factors, sales, supply, segmentation, demand, manufacture analysis, regional analysis, recent trends, and competing companies are included in the report. The exquisite data provided in global Joint Pain Injections market research report is explanatory in terms of quantity as well as quality.

For Better Understanding ofJoint Pain Injections Market

DOWNLOAD FREE SAMPLE PDF COPY

Competitive Landscape of Joint Pain Injections Market Includes Leading Companies Such As:

Allergan Plc., Pfizer Inc, Sanofi, Anika Therapeutics Inc, Ferring B.V., Bioventus LLC, Flexion Therapeutics Inc, Zimmer Biomet Holdings Inc, Seikagaku Corporation, Chugai Pharmaceutical Co Ltd

Joint Pain Injections Market Segmentation Includes:

Segmentation by Injection type:

Corticosteroid InjectionsHyaluronic Acid InjectionsOthers (include, Platelet-rich plasma (PRP), Placental tissue matrix (PTM), etc.)Segmentation by joint type:

Knee & AnkleHip JointShoulder & ElbowFacet Joints of the SpineOthers (include, Ball and socket, etc.)Segmentation by end-user:

Hospital PharmaciesRetail PharmaciesOnline Pharmacies

To Claim Exclusive Offer,Inquire/Speak To ExpertAbout Joint Pain InjectionsMarketResearchReport:https://marketresearch.biz/report/joint-pain-injections-market/#inquiry

The research report provides in-depth analysis on:

The growth rate along with size and share of the Joint Pain Injections Market during the Historic period.

The prime factors expected to drive the Joint Pain Injections Market for the estimated period.

The major market-leading Companies and what has been their business winning strategy for success so far.

Significant trends shaping the growth prospects of the Joint Pain Injections Market.

The Forecast of the Joint Pain Injections Market by Sales, Revenue, Growth Rate and Regions.

In addition to the data part, the report also provides an overview of Joint Pain Injections, including classification, application, industry chain analysis and latest market dynamics.

If you have any Customization need to be added, we are happy to servehttps://marketresearch.biz/report/joint-pain-injections-market/#request-for-customization

About Us

MarketResearch.biz is a global market research and consulting service provider specialized in offering a wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in todays competitive environment and thus, we have collaborated with industrys leading research providers who work continuously to meet the ever-growing demand for market research reports throughout the year.

Contact Us:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

Continued here:
Exclusive Research On Joint Pain Injections Market SWOT Analysis including Key Players - Sound On Sound Fest

Pike River widow ‘on the up’ after stem cell treatment for cancer – Stuff.co.nz

Pike River widow Anna Osborne is "on the up" and out of hospital in time for Christmas.

Osborne, whose husband Milton died in the 2010 Pike River mine disaster, had stem-cell treatment for Hodgkinlymphoma in October.

She had been told she only had a month to a year to live without it.

Phil Walter/Getty

Anna Osborne, from the Pike River Family Reference Group, embraces Prime Minister Jacinda Ardern at the mine entrance earlier this year.

Friend and Pike River mother SonyaRockhouse said Osborne's treatment went well, but there was still a long road ahead.

READ MORE:*Pike River mine tunnel entry an important moment for widow*Pike River re-entry team breaks through into mine drift*Pike River widow 'full of nerves' for mine drift re-entry*The road to getting back into Pike River

"I think the treatment is working for now. She just got her bloods done and they were good and they are the most important thing," she said.

Kevin Stent/Stuff

Osborne and Sonya Rockhouse at the announcement the Government would re-enter the Pike River mine.

Osbornewasdiagnosed with Hodgkinlymphoma in 2002 when she was 36.

She had radiation for six weeks and went into remission, but the cancercame back just before the Pike River tragedy in November 2010, when 29 men where killed in a series of explosions at the coal mine. Osborne helped campaign for thelegalisation of medicinal cannabiswhile undergoing chemotherapy in 2015.

Her stem-cells wereharvested and frozenin August. The stem cell transplanttook place in Christchurch in October aftersix days of intensive chemotherapy.

JOANNE CARROLL/Stuff

Anna Osborne, pictured during treatment for Hodgkins lymphoma in 2016.

The treatment had its own risks.

Osborne was in isolation for five weeks but after shereturned home, she hadsome set backs and small complications,Rockhousesaid.

"She was so crook. She lost a lot of weight. She's had two or three trips to hospital since then," she said.

Supplied/Pike River Recovery Agency

Mine worker Bryan Heslip offers a hand to Osborne and Rockhouse after entering the Pike River mine drift during the re-entry operation.

"She's on the up now,but [there is] still a long way to go. She's at home and is getting some colour back in her cheeks, [and is] starting to look like her old self."

Rockhouse said Osborne was focusing on her recovery and hoped to be able to go to the Pike River mine for the next milestone, which was removing the 170m seal expected to take place in January.

Continued here:
Pike River widow 'on the up' after stem cell treatment for cancer - Stuff.co.nz

California Proposed Initiative Enters Circulation: Authorizes Bonds to Continue Funding Stem Cell and Other Medical Research – Sierra Sun Times

December 19, 2019 - SACRAMENTO, CA- Secretary of State Alex Padilla announced that the proponent of a new initiative was cleared to begin collecting petition signatures.

The Attorney General prepares the legal title and summary that is required to appear on initiative petitions. When the official language is complete, the Attorney General forwards it to the proponent and to the Secretary of State, and the initiative may be circulated for signatures. The Secretary of State then provides calendar deadlines to the proponent and to county elections officials. The Attorney Generals official title and summary for the measure is as follows:

AUTHORIZES BONDS TO CONTINUE FUNDING STEM CELL AND OTHER MEDICAL RESEARCH. INITIATIVE STATUTE.Authorizes $5.5 billion in state general obligation bonds to fund grants from the California Institute of Regenerative Medicine to educational, non-profit, and private entities for: (1) stem cell and other medical research, therapy development, and therapy delivery; (2) medical training; and (3) construction of research facilities. Dedicates $1.5 billion to fund research and therapy for Alzheimers, Parkinsons, stroke, epilepsy, and other brain and central nervous system diseases and conditions. Limits bond issuance to $540 million annually. Appropriates money from General Fund to repay bond debt, but postpones repayment for first five years. Summary of estimate by Legislative Analyst and Director of Finance of fiscal impact on state and local governments:State costs of $7.8 billion to pay off principal ($5.5 billion) and interest ($2.3 billion) on the bonds. Associated average annual debt payments of about $310 million for 25 years. The costs could be higher or lower than these estimates depending on factors such as the interest rate and the period of time over which the bonds are repaid. The state General Fund would pay most of the costs, with a relatively small amount of interest repaid by bond proceeds.(19-0022A1.)

The Secretary of States tracking number for this measure is 1880 and the Attorney General's tracking number is 19-0022.

The proponent of the measure, Robert N. Klein, must collect signatures of 623,212 registered voters (five percent of the total votes cast for Governor in the November 2018 general election) in order to qualify it for the ballot. The proponent has 180 days to circulate petitions for the measure, meaning the signatures must be submitted to county elections officials no later than June 15, 2020*. The proponent can be reached c/o James C. Harrison of Remcho, Johansen & Purcell, LLP at (510) 346-6203. The address for Remcho, Johansen & Purcell, LLP is 1901 Harrison Street, Suite 1550, Oakland, CA 94612.

*Date adjusted for official deadline, which falls on a Sunday (Elec. Code 15)Source: CA. SOS

Follow this link:
California Proposed Initiative Enters Circulation: Authorizes Bonds to Continue Funding Stem Cell and Other Medical Research - Sierra Sun Times

Waning treatment is a warning for all ‘one-and-done’ therapies – STAT – STAT

As a new mother, she didnt know to look for blue-tinged lips. She could just tell her babys color was off. On a chest X-ray, the clean, white-against-dark curves of his ribs were obscured, clouded by fluid. Pneumonia. That tipped Ray Ballards physicians off: He had a form of severe combined immunodeficiency SCID, for short a genetic mutation that hampered the growth of crucial immune cells, leaving him utterly vulnerable to infection.

The best fix was a transplant of his mothers bone marrow. The attitude was that in three to six months, you should be able to go back to normal life, recalled his mom, Barb Ballard.

That was true at least sort of. He got two more booster transplants before he hit 10. An antibiotic left him with hearing loss, and a virus with digestive tract damage. His lack of B cells meant he needed regular injections of other peoples antibodies, and his T cell counts were never ideal. But he was healthy enough to go to public school, to move through the hallways high-fiving half the guys, to slowly inhale and take aim during rifle team practice.

advertisement

His T cells had to be working well enough that he wasnt coming down with everything that walked into the classroom, Ballard said.

Then, when Ray was around 18, his immunity began to wane. For him, it came in the form of a norovirus he couldnt shake. For others with the same rare disease, it appears as pneumonia or gastrointestinal trouble or an unexpected T cell decline. Over the last 10 years, the trend has become increasingly clear: The bone marrow transplants that kept certain babies with SCID alive sometimes stop working after years or decades of providing fairly reliable immune defenses.

Now, to patient advocates, this has become an urgent lesson in the language people use to talk about treatment and not just for SCID. They see their communitys experience as a cautionary tale for anyone developing or receiving a therapy thats marketed as potentially curative.

Theres an expectation and a hope: When they hear about bone marrow transplants, it sounds like a lifetime deal, a forever fix, said John Boyle, president and CEO of the Immune Deficiency Foundation. Weve discovered, as a result of this issue, that bone marrow transplant ended up not being the forever fix we thought it was.

Experts have known for years that some of these transplants wouldnt provide full immune protection over the course of a SCID patients entire life. They say clinicians should have avoided the word cure. But even scientific papers that hinted at such complications called the treatment curative. Just this year, an Immune Deficiency Foundation employee was given the unenviable task of sifting through the organizations thousands of pages of online material, scrubbing out every cure that popped up. It was only there a handful of times sometimes in quotes from clinicians, Boyle said but it was there and it needed to be removed.

The language patients hear can sometimes even change their outcomes. Weve heard of cases where, years later, they realized their immune system isnt as healthy as they thought, but nobody was tracking that because they hadnt maintained a relationship with the physician, or the physician didnt maintain a relationship with them, explained Ballard. The word cure, it gives them a false sense of security.

At a time when seemingly every biotech is promoting the idea of one-and-done therapies and setting prices accordingly these advocates hope companies, too, will be more wary. One of the things Im trying to make them very aware of is the need for lifelong follow-up, said Heather Smith, who runs the SCID Angels for Life foundation. For her, its personal: This summer, her son took part in a clinical trial for a gene therapy in the hope that it would provide the immune protection that his decades-old bone marrow transplant no longer could. My son will be followed for 15 years, she said. But what about after that?

Part of the issue with bone marrow transplants from one person to another is the natural genetic variation between us, particularly in the proteins that help our bodies distinguish its own cells from foreign ones. Receiving cells from someone whose proteins dont match yours could cause a civil war within you. Thats why bone marrow transplants began back in the 1950s with identical twins: Sharing those genes meant increasing the likelihood of harmony between the body and the graft.

But the vast majority of people dont have a protein-matched sibling, let alone an identical twin. So researchers set about figuring out how to transplant bone marrow from a parent to a child in spite of only sharing half of their genes and from a matched unrelated donor to a stranger. Like cooks intent on refining recipes to their taste, the doctors who adapted the technique for SCID often did so slightly differently from one another. Over the past 35 years, those idiosyncrasies have hardened into habits. Right now, everybody transplants their patients their way, said Dr. Sung-Yun Pai, an immune deficiency researcher and co-director of the gene therapy program at Boston Childrens Hospital.

Perhaps the most vociferous controversy has been about whether to use chemotherapy to wipe out the existing stem cells within a recipients bone marrow to make room for the donors. The doctors who do use chemo before a transplant might prescribe different doses; others forego it entirely.

The arguments were sound on both sides. On the one hand, the toxic drugs could clean out the niches within our bone and increase the chances that the donors cells take root. On the other, these chemicals could hamper growth, brain development, and fertility, could make an infant who was already sick even sicker, and could increase the likelihood of certain cancers later in life. Its like being exposed to a bunch of X-rays and sunlight, or other DNA-damaging agents, Pai explained.

Because SCID is so rare the most common subtype is thought to occur in 1 out of every 50,000 to 100,000 newborns and because every hospital was doing transplants slightly differently, it was hard for physicians to systematically study what was working best. But even early on, they could tell that some of the infants whod gotten no chemo were developing incomplete immune systems. They didnt produce their own B cells, for instance, and so needed regular injections of antibodies collected from other peoples blood.

In healthy infants, stem cells migrate from the crevices of the skeleton to an organ in the chest called the thymus, where theyre trained to become T cells. In these infants, the T cell counts grew after transplant but it wasnt necessarily because the sludge was securely taking hold in the niches of their bones. Rather, immunologists say, the donors progenitor cells were only transient. Some were able to head toward the thymus for schooling. Some graduated and started fighting off infections. But as those populations were depleted with age, there werent robust reserves of stem cells in the bone marrow that could arrive to produce more. To Pai, its like trying to fill a kindergarten class in a neighborhood where no ones having babies.

You and I continue to have a slow trickle of new T cells coming out, said Dr. Harry Malech, a senior investigator at the National Institutes of Health, who sits on the board of a gene therapy company, Orchard Therapeutics (ORTX), but does not receive any financial compensation. Instead of a torrent becoming slower, in these patients it goes from a trickle to practically nothing.

Thats why immunity starts to wane in kids like Ray Ballard. To many immunologists, it isnt a surprise, though they still arent sure why chemo-less transplants last longer for some of these kids than others. They can also understand how some families and clinicians might have viewed this treatment as a lifetime fix.

As Malech put it, If I said to you, Your child, instead of dying in infancy, will likely get to adulthood, go to school, have a normal life, you might think the word cure in your mind.

Even for parents who knew the protection might not last forever, the failure of a long-ago bone marrow transplant puts them in a bind. If they do nothing, their child will once again be vulnerable to any passing infection, which could prove fatal. They can try another round of the same procedure, though booster transplants sometimes come with added complications. Or they can try getting their child into a research trial for gene therapy, which comes with the risks of any experimental treatment.

Some feel an irrational guilt when the bone marrow they donated to their child stops functioning. Its your cells, and if it doesnt work, you failed them, said Ballard, who lives in Clifton, Va., about a 40-minute drive from Washington, D.C. Her son Ray had already had three transplants as a child. When his immune system started to fail again in early adulthood, gene therapy at the NIH seemed like the only reasonable choice.

That would involve researchers removing cells from his bone marrow, using an engineered virus as a kind of molecular syringe to slip in a healthy copy of the gene in which he had a defect, and then threading these corrected cells back into his veins a bone marrow transplant to himself. But preparing a virus can be tricky, and there were delays.

Meanwhile, Rays condition was getting worse. His norovirus was preventing him from absorbing much nutrition, and as Ballard put it, his bone structure was just crumbling at that point. His doctors told her he had the skeleton of an 85-year-old.

He died this past February, at 25 years old. One friend got his birth and death dates tattooed onto her shoulder. Another painted a portrait of him for Ballard, in which his arms are crossed, his lips pressed together in a wry smile.

At Boston Childrens, Pai is now helping to lead a randomized trial to better understand what dose of chemo works best for SCID patients receiving transplants. Over the last decade or so, she, Malech, and many other clinicians have also teamed up to track the long-term results of immune deficient patients whove received someone elses bone marrow.

Pai is hopeful that knowing about the phenomenon of waning immunity will give gene therapies a better shot at becoming a durable fix. They probably have a better chance of achieving a one-time, lifelong cure, but its never wrong to be humble, she said. Only after decades more and hundreds or thousands of patients will we know for sure.

Patient advocates point out that even then, these patients will still have the capacity of passing on their SCID-causing gene to future generations, and so the word cure is overly optimistic. Thats why I like the word remission, said Smith. That still gives you the hope. If you were given a cancer diagnosis, you wouldnt go through treatment and then just forget about it for the rest of your life.

As Boyle put it, Weve seen the promise and then weve seen the reality. Everyone who is looking at a transformational therapy should be optimistic, but also realistic, and not assume that this is truly one and done. (Boyles foundation has received financial support from Orchard Therapeutics, which is developing a gene therapy for a form of SCID.)

To Amy Saada, of South Windsor, Conn., that isnt theoretical. Her son Adam is now 12, and the immunity from the bone marrow transplant he got as a baby is wearing off. He isnt yet sick, but his parents know they need to decide between gene therapy or another transplant soon. She has a very clear memory of how long and uncertain the recovery from treatment felt. In some ways, she wishes she didnt know quite as much as she does; that way, she would feel less trepidation about what lies ahead.

Your heart kind of sinks, she said. Youve already been through it once, and it was hell. Its harder the second time.

See the rest here:
Waning treatment is a warning for all 'one-and-done' therapies - STAT - STAT

Evotec Achieves Third Milestone In Cell Therapy Diabetes Alliance With Sanofi – Yahoo Finance

HAMBURG, GERMANY / ACCESSWIRE / December 19, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced successful achievement of a third milestone in their diabetes research alliance with Sanofi ("TargetBCD"), resulting in a payment of 3 m to Evotec.

This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme. The ultimate goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are extremely pleased with the progress we are making on this beta cell therapy approach which has the potential to restore beta cell function and, thereby, address the root cause of diabetes rather than only its symptoms."

About the Evotec-Sanofi-Alliance in Diabetes ("TargetBCD")In August 2015, Evotec and Sanofi announced a research alliance to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells for diabetes. Both companies have made significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration, which is a key value-driving relationship under the Company's EVT Innovate business segment, extends Evotec's metabolic disease and stem cell-based drug discovery programmes. To date, Evotec has received 12 m in upfront and milestone payments from Sanofi, as well as substantial research funding.

About DiabetesDiabetes mellitus ("diabetes") is a chronic incapacitating disease associated with severe lifelong conditions which require intensive monitoring and control, such as cardiovascular diseases, kidney diseases, nerve damage and eye diseases. At present, there is no cure for diabetes and only symptomatic treatment options are available. According to the International Diabetes Federation, approximately 425 million people worldwide suffered from diabetes in 2017 (2015:415 million). The disease is a major burden to the global healthcare systems with $ 727 bn being spent on the treatment of diabetes in 2017 (2015: $ 673 bn).

About Beta CellsBeta cells play a key role in the pathogenesis of diabetes. Beta cells reside in clusters of hormone producing cells ("islets") within the pancreas. They respond to elevated blood glucose levels (e.g. after a meal) by secreting the glucose lowering hormone insulin. In the type 1 form of diabetes ("T1D"), beta cells are destroyed by the patient's own immune system. As a result, T1D patients have to follow a life-long regimen of carefully-dosed insulin injections. In patients with type 2 diabetes ("T2D"), beta cells are functionally impaired and yet have to work in the presence of metabolic stress and increased work load due to an impaired tissue insulin response. T2D is progressive, and current therapeutic options cannot prevent the deterioration of beta cell function, eventually also creating a need for insulin injections. Despite the fact that insulin treatments are important and widely used for people with diabetes, they cannot fully mimic the normal control of blood glucose levels by normal beta cells necessary to avoid acute and long-term complications of diabetes. There is a critical medical need for novel therapeutic options which can restore beta cell mass and, thereby, reduce or eliminate the need for insulin injections. Furthermore, beta cell replacement therapy also has the potential to prevent or reverse the decline in beta cell function in type 2 diabetes.

ABOUT EVOTEC SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

FORWARD LOOKING STATEMENTSInformation set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:Gabriele Hansen, SVP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

Story continues

Link:
Evotec Achieves Third Milestone In Cell Therapy Diabetes Alliance With Sanofi - Yahoo Finance

A new role for a triple-negative breast cancer target – Penn: Office of University Communications

Unlike almost every other organ, the mammary gland does not develop until after birth. And its unusually dynamic, shape-shifting during menstrual cycles, puberty, pregnancy, and lactation.

These changes require energy. In a study usinga new, genetically altered mouse model, researchers led by Rumela Chakrabarti of Penns School of Veterinary Medicine haveuncovered a key protein involved in supplying the mammary gland with fuel during puberty. Its a protein that her group had earlier shown to play a role in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease.

Besides illuminating an important feature of mammalian biological development, the findings also give reassurance that targeting this protein, known as deltaNp63, to treat cancer in adults could be done without interfering with critical developmental stages that occur later in life.

Creating a new mouse model that allows us to control when p63 is expressed enabled us to study this molecule in different developmental stages, Chakrabarti says of the work, published in the journal FEBS Letters. The fact that it is not required later on after puberty means that its a viable drug target for triple-negative breast cancer. And we think it could be applicable to other cancers, like squamous cell carcinomas and esophageal cancer as well.

Chakrabarti has focused on this molecule since her postdoctoral fellowship, revealing different features of its involvement in the mammary gland stem cells that give rise to every other cell type in the mammary gland tissue. In 2014, Chakrabarti and colleagues found it was important in initiating TNBC, and last year they demonstrated that it also acts to direct a type of immune cell to breast tumors, serving to aggravate the progression and spread of cancer.

Weve found that this molecule is like a master regulator, says Chakrabarti. It can regulate the tumor cells stem cell activity, and it can regulate the immune cells around the tumor cells. But we also wanted to know how it acted in normal cells.

To do that, the researchers fashioned a new strain of mice in which they could deplete the animals of deltaNp63 as desired. With this mouse model in hand, they were able to assess how deleting that gene affected the mammary gland.

While inducing the deletion of deltaNp63 during pregnancy and adulthood had no significant effect on mammary gland development and function, the team found significant impacts arose when deletion occurred during puberty.

It may be that the initial burst of energy that is required during puberty depends on deltaNp63, but once you get through that, it isnt as critical, says Chakrabarti.

Losing the protein during puberty led to a reduction in energy production in the mammary gland cells and caused mammary gland ducts to be malformed. Further analysis suggests that deltaNp63 likely activates other proteins that are involved in both cellular metabolism and in the organization of cell structure during puberty.

We already knew that p63 was important for mammary gland stem cells, but we didnt know that it was involved in regulating the cells metabolism, Chakrabarti says. Mammary stem cells have a high energy need during the extensive tissue remodeling that occurs during puberty. Cancer cells also have a high energy need. So this finding helps tie together a number of roles that p63 seems to be playing in the mammary gland.

In follow-up work, Chakrabartis lab is investigating the connection between metabolism and TNBC, with an eye toward pursuing deltaNp63 as a possible therapeutic target to slow down the spread of disease.

Rumela Chakrabarti is an assistant professor of biomedical sciences in the University of Pennsylvania School of Veterinary Medicine.

Chakrabartis coauthors from Penn Vet were first author Sushil Kumar, Ajeya Nandi, and Aakash Mahesh. In addition, Satrajit Sinha of the State University of New York at Buffalo and Elsa Flores of the Moffit Cancer Center coauthored the paper.

Support for the study came from the Penn Vet Comparative Pathology Core, the Flow Cytometry Core at the University of Pennsylvania and Childrens Hospital of Philadelphia.

Read the original:
A new role for a triple-negative breast cancer target - Penn: Office of University Communications

Adipose Derived Stem Cell Therapy Market 2018: Report Highlights the Competitive Scenario with Impact of Drivers and Challenges to 2026 – Market…

Global Adipose Derived Stem Cell Therapy Market Size, Status and Forecast 2018-2026offers a primary overview of the Adipose Derived Stem Cell Therapy industry covering Definition, Classification, Industry Value, Price, Cost and Gross Profit, Share via Region, New Challenge Feasibility Evaluation, Analysis and Guidelines on New mission Investment. Adipose Derived Stem Cell Therapy Market report presents in-intensity insight of Company Profile, Capacity, Product Specifications, Production Value, Sales, Revenue, Price, Gross Margin, Market Size and Market Shares for topmost prime key vendors: BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.. In the end, there are 4 key segments covered in this Adipose Derived Stem Cell Therapy market report: competitor segment, product type segment, end use/application segment and geography segment.

Target Audience of Adipose Derived Stem Cell Therapy Market: Suppliers, Channel Partners, Production Companies, Market Consultants, Marketing Authorities, Research Institutions, Subject Matter Experts, Financial Institutions, Government Authorities.

To Get the Concise Free Sample PDF of the Adipose Derived Stem Cell Therapy Market Report, Along With the TOC, Statistics, and Tables Please Visit

Adipose Derived Stem Cell Therapy Market Summary: This report includes the estimation of market size for value (million US$) and volume (K sqm). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Adipose Derived Stem Cell Therapy market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Based on Classifications, each type is studied as Sales, Adipose Derived Stem Cell Therapy Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. each type, including:

Adipose Derived Stem Cell Therapy Market Taxonomy:-

The global adipose derived stem cell therapy market is segmented on the basis of cell type, product type, application, end user, and region.

By Cell Type

By Product Type

By Application

By End User

By Region

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert

Adipose Derived Stem Cell Therapy Market: Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (the United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)Industrial Chain, Sourcing Strategy and Downstream Buyers (2018 2026)

Industrial Chain Analysis of Adipose Derived Stem Cell Therapy market:

Adipose Derived Stem Cell Therapy Market Capacity, Production and GrowthProduction, Consumption, Export and ImportRevenue and Growth of MarketAdipose Derived Stem Cell Therapy Market Forecast (2018 2026)

Adipose Derived Stem Cell Therapy Market by Capacity, Production, Revenue ForecastProduction Forecast by Type and Price ForecastConsumption Forecast by ApplicationProduction, Import, Export and Consumption ForecastAdipose Derived Stem Cell Therapy Market Production, Consumption, Import and Export Forecast by Regions (Provinces)

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: [emailprotected]

This post was originally published on Market Research Sheets

Read more:
Adipose Derived Stem Cell Therapy Market 2018: Report Highlights the Competitive Scenario with Impact of Drivers and Challenges to 2026 - Market...